BUSINESS

Sawai Further Delays Manufacturing Start at Trust Pharmatech Unit

January 11, 2024

Saiwai Group Holdings said on January 10 that it will further push back the resumption of manufacturing operations at its subsidiary Trust Pharmatech scheduled for this week as repair work after the earthquake is taking longer than expected.

The central Japan tremblor caused cracks in some of the buildings at Trust’s three plants in Fukui Prefecture. Although the company was originally planning to bring the sites back online for this year on January 4, it previously told Jiho that it was pushing back the date to sometime in the week of January 9 due to inspections. On January 10, Sawai said that the date will be further delayed to sometime in the week of January 15.

The recovery work for water supply/drainage systems as well as air conditions at the quake-damaged buildings is taking longer than initially expected, said the generic giant. However, there will be no drug supply issues related to this delay as there are enough products in inventory, it said.

Trust manufacturers allopurinol 100 mg tablet products and takes on some processes for esomeprazole capsules 20 mg.

Related Article

BUSINESS

Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…

By Takashi Ebisawa

Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…

By Philip Carrigan

Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…

Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…

By Ken Yoshino

The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…

The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…

Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…

Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…